Pardes Biosciences, Inc

FS Development Corp. II, trading under the ticker FSII, was a blank-check company sponsored by Foresite Capital Management that launched its initial public offering in 2021 with a focus on the biotechnology and pharmaceutical sector. The SPAC announced a business combination with Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company developing oral antiviral therapies, on June 29, 2021. The transaction has since closed. Pardes Biosciences was advancing direct-acting antiviral candidates targeting respiratory viruses, making it a notable life-sciences SPAC deal within the busy 2021 merger cycle. Sign up for full data access on SpacDesk to explore complete filing history, deal timelines, and institutional activity across this and hundreds of other SPAC transactions.

SPAC Counterparty (1)